NCT06125691 - Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults | Biotech Hunter

Enrollment

139

Participants

Timeline

Start Date

January 22, 2024

Primary Completion Date

August 10, 2024

Study Completion Date

January 7, 2025

Conditions

Influenza, Human

Interventions

BIOLOGICAL

ARCT-2138

Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.

BIOLOGICAL

Licensed Quadrivalent Vaccine for younger adults

Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.

BIOLOGICAL

Licensed Quadrivalent Vaccine for older adults

Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.

Trial Locations (2)

Emeritus Research Camberwell, Melbourne

Nucleus Network Brisbane Clinic, Brisbane